Sintilimab, a novel anti-PD-1 agent with or without IBI305, a biosimilar of bevacizumab, plus chemotherapy in EGFRm NSCLC after progression on EGFR-TKI significantly prolonged mPFS (6.9 versus 4.3 months; HR 0.464, 95% CI: 0.337, 0.639; p < 0.0001) and increased ORR (43.9 versus 25.2%) in comparison with chemotherapy alone [175]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.